3 Investable Laggards In An Overbought Market
My Top 3 Pharma Stocks
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB)
3 Potential Biotech Acquisition Targets
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push
ETNB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 89bio, Inc. Is Fair to Shareholders
Roche to buy US biotech 89bio in $3.5bn deal
Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders
Roche to Buy 89bio for Up to $3.5 Billion
Roche to acquire liver drug developer 89bio for up to $3.5 billion
89bio, Inc. Announces Agreement to be Acquired by Roche
89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript
89bio: Promising As Pegozafermin Nears Phase 3 Readout
89bio (ETNB) Q2 R&D Jumps 131%
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio to Participate in Upcoming Investor Conferences
89bio Reports First Quarter 2025 Financial Results and Corporate Updates
89bio: A Buy With Strong Market Opportunity In MASH And SHTG
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
89bio to Participate in the Leerink Partners Global Healthcare Conference
89bio price target lowered by $8 at H.C. Wainwright, here's why
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Should You Buy 89BIO (ETNB) After Golden Cross?
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
Insider Buying Surges in February, Especially in These 6 Stocks
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet
89bio's Pegozafermin Is Now Gaining Momentum
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Why 89bio Stock Lagged the Market Today
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
New Strong Sell Stocks for January 7th
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New Strong Sell Stocks for November 16th
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants